Traditional commercialization strategies that once fueled massive growth and profitability are no longer viable in today’s complex and competitive market.
High SG&A costs without resulting revenue, patent cliffs, rising patient acquisition costs, convoluted supply chain management, fragmented execution, lack of pricing transparency, and complicated relationships with PBMs are some of the internal and external pressures straining the financial health of manufacturers.
As a result, manufacturers must transition from traditional large field teams to a high-impact field strategy, effectively scaling resources and optimizing operations. This approach drives growth and profitability, helping to mitigate challenges such as patent cliffs and policy changes. In our latest article, our experts explain how our direct-to-patient model drives growth and profitability to mitigate major marketing challenges.
What are the key benefits of EVERSANA DIRECT CommercializationTM?
- Drives a 30-50% reduction in patient acquisition costs
- Shortens time to diagnosis and therapy by 85% and achieves a 70% adherence rate
- Streamlines distribution and accelerates medication delivery
- Enhances transparency and averts revenue leakage
- Offers cost efficiency by operating independently of PBMs
Download the article to learn more about how a direct-to-patient model is the future of commercialization.
Author
As President of EVERSANA, Greg is responsible for accelerating the company’s growth and ensuring the success of all client commercialization efforts. With more than 25 years of executive leadership, Greg understands all facets of…